Loading…

Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma

The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion,...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pathology 2018-03, Vol.244 (3), p.283-295
Main Authors: Kucia‐Tran, Justyna A, Tulkki, Valtteri, Scarpini, Cinzia G, Smith, Stephen, Wallberg, Maja, Paez‐Ribes, Marta, Araujo, Angela M, Botthoff, Jan, Feeney, Maria, Hughes, Katherine, Caffarel, Maria M, Coleman, Nicholas
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33
cites cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33
container_end_page 295
container_issue 3
container_start_page 283
container_title The Journal of pathology
container_volume 244
creator Kucia‐Tran, Justyna A
Tulkki, Valtteri
Scarpini, Cinzia G
Smith, Stephen
Wallberg, Maja
Paez‐Ribes, Marta
Araujo, Angela M
Botthoff, Jan
Feeney, Maria
Hughes, Katherine
Caffarel, Maria M
Coleman, Nicholas
description The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
doi_str_mv 10.1002/path.5010
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2001686182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2001686182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</originalsourceid><addsrcrecordid>eNp1kL9u2zAQh4miQeP8GfoCAYFOHeSQlEiLo2GkcQAXzeDMAkUeawaSKJNSUm8d8gB9xj5J6DgtkCHTAXfffYf7IfSZkiklhF32athMOaHkA5pQIkUmSyk-okmasSwv6OwYncR4TwiRkvNP6JhJRngu2AQ9zbvB_f39x3fax0ENrsPfsUq92psddt3G1W6IeNgA7oNPYKsa97NLBAZrQaeZt_jNdgAN_eAD9g8Q4FcfIEbnuyTDcTuq1o8Ra2garFXQrvOtOkNHVjURzl_rKbr7drVeLLPVj-ubxXyV6YIXJCtKy6wysyKXVjMuC1PqPFeKgzFGc8o0NayeWZB5zUqrTS2pnQkQXDAi6jw_RV8O3vTKdoQ4VPd-DF06WTFCqCgFLVmivh4oHXyMAWzVB9eqsKsoqfZ5V_u8q33eib14NY51C-Y_-S_gBFwegEfXwO59U3U7Xy9flM8NPI-n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2001686182</pqid></control><display><type>article</type><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</creator><creatorcontrib>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</creatorcontrib><description>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.5010</identifier><identifier>PMID: 29205362</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Activation ; Angiogenesis ; Animals ; Antineoplastic Agents, Immunological - pharmacology ; Autocrine Communication ; Autocrine signalling ; Blocking antibodies ; Cell Line, Tumor ; Cervical carcinoma ; Cervix ; Copy number ; Female ; Gene Expression Regulation, Neoplastic ; head and neck ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - immunology ; Head and Neck Neoplasms - metabolism ; Head and Neck Neoplasms - pathology ; Humans ; Janus Kinase 2 - genetics ; Janus Kinase 2 - metabolism ; Lung Neoplasms - drug therapy ; Lung Neoplasms - immunology ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Metastases ; Metastasis ; Mice, Inbred NOD ; Mice, SCID ; neutralizing antibodies ; Oncostatin M ; Oncostatin M - genetics ; Oncostatin M - metabolism ; oncostatin M receptor ; Oncostatin M Receptor beta Subunit - antagonists &amp; inhibitors ; Oncostatin M Receptor beta Subunit - genetics ; Oncostatin M Receptor beta Subunit - immunology ; Oncostatin M Receptor beta Subunit - metabolism ; Phosphorylation ; Secretion ; Signal Transduction ; SOCS-3 protein ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - immunology ; Squamous Cell Carcinoma of Head and Neck - metabolism ; Squamous Cell Carcinoma of Head and Neck - pathology ; STAT3 ; Stat3 protein ; STAT3 Transcription Factor - genetics ; STAT3 Transcription Factor - metabolism ; Suppressor of Cytokine Signaling 3 Protein - genetics ; Suppressor of Cytokine Signaling 3 Protein - metabolism ; Up-Regulation ; Uterine Cervical Neoplasms - drug therapy ; Uterine Cervical Neoplasms - immunology ; Uterine Cervical Neoplasms - metabolism ; Uterine Cervical Neoplasms - pathology ; Xenograft Model Antitumor Assays</subject><ispartof>The Journal of pathology, 2018-03, Vol.244 (3), p.283-295</ispartof><rights>Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</rights><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</citedby><cites>FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</cites><orcidid>0000-0002-3331-1249 ; 0000-0002-5374-739X ; 0000-0001-8784-7025 ; 0000-0003-4730-5197 ; 0000-0002-7442-6827 ; 0000-0001-7744-3238</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29205362$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kucia‐Tran, Justyna A</creatorcontrib><creatorcontrib>Tulkki, Valtteri</creatorcontrib><creatorcontrib>Scarpini, Cinzia G</creatorcontrib><creatorcontrib>Smith, Stephen</creatorcontrib><creatorcontrib>Wallberg, Maja</creatorcontrib><creatorcontrib>Paez‐Ribes, Marta</creatorcontrib><creatorcontrib>Araujo, Angela M</creatorcontrib><creatorcontrib>Botthoff, Jan</creatorcontrib><creatorcontrib>Feeney, Maria</creatorcontrib><creatorcontrib>Hughes, Katherine</creatorcontrib><creatorcontrib>Caffarel, Maria M</creatorcontrib><creatorcontrib>Coleman, Nicholas</creatorcontrib><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><title>The Journal of pathology</title><addtitle>J Pathol</addtitle><description>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><subject>Activation</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antineoplastic Agents, Immunological - pharmacology</subject><subject>Autocrine Communication</subject><subject>Autocrine signalling</subject><subject>Blocking antibodies</subject><subject>Cell Line, Tumor</subject><subject>Cervical carcinoma</subject><subject>Cervix</subject><subject>Copy number</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>head and neck</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - immunology</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Humans</subject><subject>Janus Kinase 2 - genetics</subject><subject>Janus Kinase 2 - metabolism</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>neutralizing antibodies</subject><subject>Oncostatin M</subject><subject>Oncostatin M - genetics</subject><subject>Oncostatin M - metabolism</subject><subject>oncostatin M receptor</subject><subject>Oncostatin M Receptor beta Subunit - antagonists &amp; inhibitors</subject><subject>Oncostatin M Receptor beta Subunit - genetics</subject><subject>Oncostatin M Receptor beta Subunit - immunology</subject><subject>Oncostatin M Receptor beta Subunit - metabolism</subject><subject>Phosphorylation</subject><subject>Secretion</subject><subject>Signal Transduction</subject><subject>SOCS-3 protein</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - immunology</subject><subject>Squamous Cell Carcinoma of Head and Neck - metabolism</subject><subject>Squamous Cell Carcinoma of Head and Neck - pathology</subject><subject>STAT3</subject><subject>Stat3 protein</subject><subject>STAT3 Transcription Factor - genetics</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>Suppressor of Cytokine Signaling 3 Protein - genetics</subject><subject>Suppressor of Cytokine Signaling 3 Protein - metabolism</subject><subject>Up-Regulation</subject><subject>Uterine Cervical Neoplasms - drug therapy</subject><subject>Uterine Cervical Neoplasms - immunology</subject><subject>Uterine Cervical Neoplasms - metabolism</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kL9u2zAQh4miQeP8GfoCAYFOHeSQlEiLo2GkcQAXzeDMAkUeawaSKJNSUm8d8gB9xj5J6DgtkCHTAXfffYf7IfSZkiklhF32athMOaHkA5pQIkUmSyk-okmasSwv6OwYncR4TwiRkvNP6JhJRngu2AQ9zbvB_f39x3fax0ENrsPfsUq92psddt3G1W6IeNgA7oNPYKsa97NLBAZrQaeZt_jNdgAN_eAD9g8Q4FcfIEbnuyTDcTuq1o8Ra2garFXQrvOtOkNHVjURzl_rKbr7drVeLLPVj-ubxXyV6YIXJCtKy6wysyKXVjMuC1PqPFeKgzFGc8o0NayeWZB5zUqrTS2pnQkQXDAi6jw_RV8O3vTKdoQ4VPd-DF06WTFCqCgFLVmivh4oHXyMAWzVB9eqsKsoqfZ5V_u8q33eib14NY51C-Y_-S_gBFwegEfXwO59U3U7Xy9flM8NPI-n</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Kucia‐Tran, Justyna A</creator><creator>Tulkki, Valtteri</creator><creator>Scarpini, Cinzia G</creator><creator>Smith, Stephen</creator><creator>Wallberg, Maja</creator><creator>Paez‐Ribes, Marta</creator><creator>Araujo, Angela M</creator><creator>Botthoff, Jan</creator><creator>Feeney, Maria</creator><creator>Hughes, Katherine</creator><creator>Caffarel, Maria M</creator><creator>Coleman, Nicholas</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0002-3331-1249</orcidid><orcidid>https://orcid.org/0000-0002-5374-739X</orcidid><orcidid>https://orcid.org/0000-0001-8784-7025</orcidid><orcidid>https://orcid.org/0000-0003-4730-5197</orcidid><orcidid>https://orcid.org/0000-0002-7442-6827</orcidid><orcidid>https://orcid.org/0000-0001-7744-3238</orcidid></search><sort><creationdate>201803</creationdate><title>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</title><author>Kucia‐Tran, Justyna A ; Tulkki, Valtteri ; Scarpini, Cinzia G ; Smith, Stephen ; Wallberg, Maja ; Paez‐Ribes, Marta ; Araujo, Angela M ; Botthoff, Jan ; Feeney, Maria ; Hughes, Katherine ; Caffarel, Maria M ; Coleman, Nicholas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Activation</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antineoplastic Agents, Immunological - pharmacology</topic><topic>Autocrine Communication</topic><topic>Autocrine signalling</topic><topic>Blocking antibodies</topic><topic>Cell Line, Tumor</topic><topic>Cervical carcinoma</topic><topic>Cervix</topic><topic>Copy number</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>head and neck</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - immunology</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Humans</topic><topic>Janus Kinase 2 - genetics</topic><topic>Janus Kinase 2 - metabolism</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>neutralizing antibodies</topic><topic>Oncostatin M</topic><topic>Oncostatin M - genetics</topic><topic>Oncostatin M - metabolism</topic><topic>oncostatin M receptor</topic><topic>Oncostatin M Receptor beta Subunit - antagonists &amp; inhibitors</topic><topic>Oncostatin M Receptor beta Subunit - genetics</topic><topic>Oncostatin M Receptor beta Subunit - immunology</topic><topic>Oncostatin M Receptor beta Subunit - metabolism</topic><topic>Phosphorylation</topic><topic>Secretion</topic><topic>Signal Transduction</topic><topic>SOCS-3 protein</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - immunology</topic><topic>Squamous Cell Carcinoma of Head and Neck - metabolism</topic><topic>Squamous Cell Carcinoma of Head and Neck - pathology</topic><topic>STAT3</topic><topic>Stat3 protein</topic><topic>STAT3 Transcription Factor - genetics</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>Suppressor of Cytokine Signaling 3 Protein - genetics</topic><topic>Suppressor of Cytokine Signaling 3 Protein - metabolism</topic><topic>Up-Regulation</topic><topic>Uterine Cervical Neoplasms - drug therapy</topic><topic>Uterine Cervical Neoplasms - immunology</topic><topic>Uterine Cervical Neoplasms - metabolism</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kucia‐Tran, Justyna A</creatorcontrib><creatorcontrib>Tulkki, Valtteri</creatorcontrib><creatorcontrib>Scarpini, Cinzia G</creatorcontrib><creatorcontrib>Smith, Stephen</creatorcontrib><creatorcontrib>Wallberg, Maja</creatorcontrib><creatorcontrib>Paez‐Ribes, Marta</creatorcontrib><creatorcontrib>Araujo, Angela M</creatorcontrib><creatorcontrib>Botthoff, Jan</creatorcontrib><creatorcontrib>Feeney, Maria</creatorcontrib><creatorcontrib>Hughes, Katherine</creatorcontrib><creatorcontrib>Caffarel, Maria M</creatorcontrib><creatorcontrib>Coleman, Nicholas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kucia‐Tran, Justyna A</au><au>Tulkki, Valtteri</au><au>Scarpini, Cinzia G</au><au>Smith, Stephen</au><au>Wallberg, Maja</au><au>Paez‐Ribes, Marta</au><au>Araujo, Angela M</au><au>Botthoff, Jan</au><au>Feeney, Maria</au><au>Hughes, Katherine</au><au>Caffarel, Maria M</au><au>Coleman, Nicholas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J Pathol</addtitle><date>2018-03</date><risdate>2018</risdate><volume>244</volume><issue>3</issue><spage>283</spage><epage>295</epage><pages>283-295</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><abstract>The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro‐malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell‐autonomous feed‐forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro‐malignant effects associated with OSMR overexpression are critically mediated by JAK–STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM–OSMR interactions. Importantly, specific inhibition of OSM–OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed‐forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM–OSMR‐blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>29205362</pmid><doi>10.1002/path.5010</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3331-1249</orcidid><orcidid>https://orcid.org/0000-0002-5374-739X</orcidid><orcidid>https://orcid.org/0000-0001-8784-7025</orcidid><orcidid>https://orcid.org/0000-0003-4730-5197</orcidid><orcidid>https://orcid.org/0000-0002-7442-6827</orcidid><orcidid>https://orcid.org/0000-0001-7744-3238</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3417
ispartof The Journal of pathology, 2018-03, Vol.244 (3), p.283-295
issn 0022-3417
1096-9896
language eng
recordid cdi_proquest_journals_2001686182
source Wiley-Blackwell Read & Publish Collection
subjects Activation
Angiogenesis
Animals
Antineoplastic Agents, Immunological - pharmacology
Autocrine Communication
Autocrine signalling
Blocking antibodies
Cell Line, Tumor
Cervical carcinoma
Cervix
Copy number
Female
Gene Expression Regulation, Neoplastic
head and neck
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - metabolism
Head and Neck Neoplasms - pathology
Humans
Janus Kinase 2 - genetics
Janus Kinase 2 - metabolism
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Metastases
Metastasis
Mice, Inbred NOD
Mice, SCID
neutralizing antibodies
Oncostatin M
Oncostatin M - genetics
Oncostatin M - metabolism
oncostatin M receptor
Oncostatin M Receptor beta Subunit - antagonists & inhibitors
Oncostatin M Receptor beta Subunit - genetics
Oncostatin M Receptor beta Subunit - immunology
Oncostatin M Receptor beta Subunit - metabolism
Phosphorylation
Secretion
Signal Transduction
SOCS-3 protein
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - drug therapy
Squamous Cell Carcinoma of Head and Neck - immunology
Squamous Cell Carcinoma of Head and Neck - metabolism
Squamous Cell Carcinoma of Head and Neck - pathology
STAT3
Stat3 protein
STAT3 Transcription Factor - genetics
STAT3 Transcription Factor - metabolism
Suppressor of Cytokine Signaling 3 Protein - genetics
Suppressor of Cytokine Signaling 3 Protein - metabolism
Up-Regulation
Uterine Cervical Neoplasms - drug therapy
Uterine Cervical Neoplasms - immunology
Uterine Cervical Neoplasms - metabolism
Uterine Cervical Neoplasms - pathology
Xenograft Model Antitumor Assays
title Anti‐oncostatin M antibody inhibits the pro‐malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90oncostatin%20M%20antibody%20inhibits%20the%20pro%E2%80%90malignant%20effects%20of%20oncostatin%20M%20receptor%20overexpression%20in%20squamous%20cell%20carcinoma&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Kucia%E2%80%90Tran,%20Justyna%20A&rft.date=2018-03&rft.volume=244&rft.issue=3&rft.spage=283&rft.epage=295&rft.pages=283-295&rft.issn=0022-3417&rft.eissn=1096-9896&rft_id=info:doi/10.1002/path.5010&rft_dat=%3Cproquest_cross%3E2001686182%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4540-48f2fad7439fc2594d8c33aa5edddc512c1d2b7fe93b28fcdb91f76e656206b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2001686182&rft_id=info:pmid/29205362&rfr_iscdi=true